You’ll have to ignore some of the immature people on here. The Biosimilars are very easy to sell. You don’t really sell them. It’s a financial sell. Our Biosimilars distinguish themselves from others by being less expensive. The Biosimilar are driven by our pricing and managed care. Biosimilars are not a clinical sell. The goals have been reasonable so far. We are still what you would consider a start up as far as our division. Managed care can be an issue, but that part is out of the sales reps hands and up to our payer/marketing team.